Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides extensive Claudin18.2 CAR-related products, you can choose the appropriate products that you desire for your research project.
Claudin18.2 (CLDN18.2) is an isoform of claudin18 and a member of the tight junction protein family. Its expression is limited in normal tissues, while abnormal expression often occurs in the development of many malignant cancers, such as gastric cancer, colon cancer, breast cancer, liver cancer, and non-small-cell lung cancer. CLDN18.2 is involved in many important biological processes, such as the proliferation, differentiation, and migration of cancer cells. Featured with its specific expression pattern and crucial biological functions, CLDN18.2 has emerged as an attractive therapeutic target for many cancers.
Fig.1 Schematic diagram of the structure of Claudin18.2.1
Associated Diseases
With years of experience in CAR-T fields, Creative Biolabs specializes in providing various robust CAR constructions, such as classical CAR design, armored CAR constructions, etc.
Fig.2 Schematic diagram of Claudin18.2 CAR construction.2
Anti-Claudin18.2 CAR Expression Assay
CAR expression detection is a very important step in CART development, so it is necessary to develop sensitive detection methods. Creative Biolabs has developed extensive CAR detection reagents (e.g., antigen-specific detection reagents, linker-specific detection antibody), as well as comprehensive detection assays to speed CART development.
Fig.3 CAR expression detection of anti-Claudin18.2 CAR-T cells by flow cytometry with representative plots (Left) and MFI percentage (right).2
Anti-Claudin18.2 CAR-T Proliferation Detection
To detect the proliferation ability of CAR-T cells, we have launched various testing services to facilitate global customers' projects, including MTT assay, CCK-8 assay, flow cytometry analysis, and CFSE-based proliferation test, etc.
Fig.4 Expansion and viability analysis of anti-Claudin18.2 CAR-T cells.2
Phenotypic Analysis of Anti-Claudin18.2 CAR-T
To characterize the functional performance of CART when co-cultured with target cells, Creative Biolabs offers comprehensive phenotypic analysis services to provide truly translational data. These assays include but are not limited to CART activation test, exhaustion test, T cell subgroup analysis, etc.
T cell Subpopulation Analysis
Fig.5 T cell subpopulation (TN, TCM, and TEM) analysis of in the CD8 (left) or CD4 (right) subsets of anti-Claudin18.2 CAR-T cells.2
Exhaustion Test of Anti-Claudin18.2 CAR-T
Fig.6 TIM-3 marker expression detection in anti-Claudin18.2 CAR-T cells on Day 7 after transduction.2
Anti-Claudin18.2 CAR-T Cytokine Release Test
Cytokine release test is often used in assessing the target specificity and effectiveness of CAR-T cells against target cells. Creative Biolabs offers various techniques for cytokine tests, such as ELISA, multiplex bead arrays, and intracellular cytokine tests by flow cytometry.
Fig.7 Cytokine (IFN-γ, IL-2, and GM-CSF) analysis of anti-Claudin18.2 CAR-T cells incubated with different tumor cells at indicated E:T ratio.2
Anti-Claudin18.2 CAR-T In Vitro Cytotoxicity Assay
To assess the target specificity and tumor-killing capability of CART cells, Creative Biolabs offers various in vitro cytotoxicity assays for customers to choose from, including chromium (51 chromium) release assays, luciferase-based cytotoxicity tests, flow cytometry-based tests, etc.
In Vitro Cytotoxicity Analysis by Luciferase Assay System
Fig.8 In vitro cytotoxicity analysis of anti-Claudin18.2 CAR-T cells against different target cells at various E:T ratios by luciferase assay system.2
In Vitro Dynamic Killing Assay
Fig.9 In vitro dynamic killing assessment of anti-Claudin18.2 CAR-T cells against different target cells by RTCA assay.2
Selecting and appropriate animal model is crucial for the proof of concept of CAR-T cell function. Creative Biolabs offers a variety of animal models to help you test information about the efficacy, distribution, and proliferation characteristics of CAR T cells in vivo.
Efficacy Test in Panc02-Claudin18.2 CDX model
Fig.10 In vivo efficacy of anti-Claudin18.2 CAR-T in Panc02-Claudin18.2 CDX model. (D) In vivo experimental design. (E) Tumor growth assessment of Panc02-Claudin18.2 CDX model treated with anti-Claudin18.2 CAR-T cells. (F) Tumor growth inhibition statistics of anti-Claudin18.2 CAR-T.2
Efficacy Test in B16F10-Claudin18.2 CDX model
Fig.11 In vivo efficacy of anti-Claudin18.2 CAR-T in B16F10-Claudin18.2 CDX model. (G) In vivo experimental design. (H) Tumor growth assessment of Panc02-Claudin18.2 CDX model treated with anti-Claudin18.2 CAR-T cells. (I) Tumor growth inhibition statistics of anti-Claudin18.2 CAR-T.2
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-ZP2640 | Anti-Claudin18A2 (CAR-ZP2640) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Human | CAR-ZP2640 | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-ZP3216 | Anti-Claudin18.2 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3388 | Anti-Claudin18.2 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0922-ZP894 | Anti-Claudin18.2 (CB-P14) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | CB-P14 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0922-ZP1204 | Anti-Claudin18.2 (CB-P14) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | CB-P14 | Rat | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX224 | Anti-Claudin18.2 (X11X224) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X224 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX225 | Anti-Claudin18.2 (X11X225) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X225 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX226 | Anti-Claudin18.2 (X11X226) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X226 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX227 | Anti-Claudin18.2 (X11X227) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X227 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX228 | Anti-Claudin18.2 (X11X228) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X228 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX229 | Anti-Claudin18.2 (X11X229) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X229 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX230 | Anti-Claudin18.2 (X11X230) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X230 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX621 | Anti-Claudin18.2 (X11X223) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X223 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX622 | Anti-Claudin18.2 (X11X224) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X224 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX623 | Anti-Claudin18.2 (X11X225) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X225 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX624 | Anti-Claudin18.2 (X11X226) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X226 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX625 | Anti-Claudin18.2 (X11X227) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X227 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX626 | Anti-Claudin18.2 (X11X228) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X228 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX627 | Anti-Claudin18.2 (X11X229) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X229 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX628 | Anti-Claudin18.2 (X11X230) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X230 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
